Datapoint: Pfizer Completes Seagen Deal
Pfizer last week completed its acquisition of oncology biotech Seagen Inc. The $43 billion deal nets Pfizer Seagen’s antibody-drug conjugate (ADC) technology, expanding its oncology pipeline to 60 programs. “This is a great day for Pfizer, and, more importantly, for people living with cancer, as we bring together the game-changing science and top talent of Seagen and Pfizer to form a leading Oncology organization,” Chris Boshoff, Pfizer’s chief oncology officer said in a press release. Norstella’s Evaluate Pharma projects Seagen’s lymphoma drug Adcetris will be its top-selling product for 2023, bringing in $998 million in global sales. The ADC currently holds covered or better status for 83% of all insured lives under the medical benefit.
SOURCE: MMIT Analytics, as of 12/15/23, and Evaluate Pharma
